Trials / Terminated
TerminatedNCT01085266
An Extension of the HORIZON Protocol Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease
HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 362 (actual)
- Sponsor
- Medivation, Inc. · Industry
- Sex
- All
- Age
- 30 Years
- Healthy volunteers
- Not accepted
Summary
An open-label extension study of the HORIZON protocol evaluating the safety of dimebon (latrepirdine)in subjects with Huntington disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dimebon (latrepirdine) |
Timeline
- Start date
- 2010-02-01
- Primary completion
- 2011-06-01
- First posted
- 2010-03-11
- Last updated
- 2016-10-12
Source: ClinicalTrials.gov record NCT01085266. Inclusion in this directory is not an endorsement.